Table 3.
(A) Toxicities observed during induction ipilimumab/nivolumab in metastatic UM
| Toxicity | Grade | Total (%) | ||||
| (A) | G1 (%) | G2 (%) | G3 (%) | G4 (%) | Unknown (%) | |
| Diarrhea/colitis | 5 (5.6) | 4 (4.5) | 10 (11.2) | 1 (1.1) | 8 (9.0) | 28 (31.5) |
| Fatigue | 8 (9.0) | 4 (4.5) | 1 (1.1) | 0 (0.0) | 7 (7.9) | 20 (22.5) |
| Hypoadrenalism | 0 (0.0) | 1 (1.1) | 2 (2.2) | 0 (0.0) | 2 (2.2) | 5 (5.6) |
| Hypophysitis | 0 (0.0) | 1 (1.1) | 3 (3.4) | 0 (0.0) | 5 (5.6) | 9 (10.1) |
| Hypothyroid | 1 (1.1) | 9 (10.1) | 0 (0.0) | 0 (0.0) | 7 (7.9) | 17 (19.1) |
| Pneumonitis | 0 (0.0) | 2 (2.2) | 2 (2.2) | 0 (0.0) | 2 (2.2) | 6 (6.7) |
| Rash | 8 (9.0) | 3 (3.4) | 3 (3.4) | 0 (0.0) | 5 (5.6) | 19 (21.3) |
| Transaminitis | 4 (4.5) | 3 (3.4) | 5 (5.6) | 1 (1.1) | 6 (6.7) | 19 (21.3) |